Nabriva clears first big hurdle in proof-of-concept study
Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat acute bacterial skin and skin structure infections. It is the first substance in a new class of systemically available pleuromutilin antibiotics for the treatment of serious skin infections and pneumonia. BC-3781 is being developed for both oral and intravenous formulations. In 207 patients recruited in 23 centers in the US, the study compared two doses of BC-3781 with Vancomycin, the gold standard for drug resistant Gram-positive bacterial skin infections. Nabriva was able to show non-inferiority compared to Vancomycin. Patients receiving BC-3781 in two different dose regimens (100mg and 150mg) showed a similar treatment success compared to Vancomycin. Nabriva is the successor of the Antibiotics Research Institute (ABRI), a former affiliate of Sandoz AG. The decision to spin-out antibiotics research in 2006 followed a strategic re-orientation of the Sandoz unit within the mother company Novartis. Nabriva’s shareholders include a big-name investor syndicate made up of Phase4 Ventures, HBM, The Wellcome Trust, GLSV and the Novartis Venture Fund.